From the Center for Value-Based Insurance Design and National Business Coalition on Health:
More evidence is piling up that clinically nuanced copayment reductions lead to improvements in medication adherence. Click here to read more background on how clinical nuance is used in benefit design.
A 2014 Journal of Managed Care Pharmacy study reported that copay reductions for Medicare beneficiaries prescribed statins resulted in a 5.9% increase in adherence over 6 months compared to those paying standard copayments. A second 2014 JMCP study found a 4.9% increase in adherence among commercially insured individuals enrolled in a $0 copayment program for generic anti-diabetic and anti-hyperlipidemic medications.
The basic premise of Value-Based Insurance Design (V-BID) is to align consumer incentives with value by reducing barriers to high-value health services and providers ("carrots"). When "carrots" are used in a clinically nuanced manner, V-BID improves health care quality and controls spending growth.